Cargando…

Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study

The COVID‐19 pandemic continues to pose challenges to the treatment of hemato‐oncology patients. Emergence of COVID‐19 variants, availability of vaccine boosters and antiviral treatments could impact their outcome. We retrospectively studied patients with hematologic malignancies and confirmed COVID...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gutwein, Odit, Herzog Tzarfati, Katrin, Apel, Arie, Rahimi‐Levene, Naomi, Ilana, Levy, Tadmor, Tamar, Koren‐Michowitz, Maya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660398/ https://www.ncbi.nlm.nih.gov/pubmed/37877352 http://dx.doi.org/10.1002/cam4.6397

Ejemplares similares

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype
por: Beider, Katia, et al.
Publicado: (2014)

Lower hemoglobin transfusion trigger is associated with higher mortality in patients hospitalized with pneumonia
por: Rahimi-Levene, Naomi, et al.
Publicado: (2018)

The impact of COVID-19 on patients with hematological malignancies: the mixed-method analysis of an Israeli national survey
por: Levy, Ilana, et al.
Publicado: (2021)

Hemoglobin transfusion trigger in an internal medicine department – A "real world" six year experience
por: Rahimi-Levene, Naomi, et al.
Publicado: (2018)

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Benjamini, Ohad, et al.
Publicado: (2021)

Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still’s Disease
por: Levy, Ofer, et al.
Publicado: (2022)

Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy
por: Barki-Harrington, Liza, et al.
Publicado: (2021)

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
por: Tadmor, Tamar, et al.
Publicado: (2021)

Time to Cure Hairy Cell Leukemia
por: Levy, Ilana, et al.
Publicado: (2017)

Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents
por: Tadmor, Tamar, et al.
Publicado: (2021)

Cellular Immune Responses to BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
por: Itchaki, Gilad, et al.
Publicado: (2021)

Hierarchical Involvement of Myeloid-Derived Suppressor Cells and Monocytes Expressing Latency-Associated Peptide in Plasma Cell Dyscrasias
por: Tadmor, Tamar, et al.
Publicado: (2018)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
por: Herishanu, Yair, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

P1622: ANTIPHOSPHOLIPID ANTIBODIES IN CONVALESCENT PLASMA OF DONORS RECOVERED FROM MILD COVID-19
por: Blickstein, D., et al.
Publicado: (2022)

Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.
por: Nakazawa, Hideyuki, et al.
Publicado: (2022)

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
por: Shibli, Rana, et al.
Publicado: (2021)

Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy
por: Michowitz, Yoav, et al.
Publicado: (2019)

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
por: Massarweh, Amir, et al.
Publicado: (2021)

Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination
por: Algaissi, Abdullah, et al.
Publicado: (2022)

Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan
por: Marumo, Yoshiaki, et al.
Publicado: (2023)

A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity
por: Michelis, Regina, et al.
Publicado: (2019)

Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients
por: Pri-Paz Basson, Yael, et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination
por: Puro, Vincenzo, et al.
Publicado: (2021)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
por: Mittelman, Moshe, et al.
Publicado: (2022)

Posterior ocular manifestations following BNT162b2 mRNA COVID-19 vaccine: a case series
por: Pillar, Shani, et al.
Publicado: (2022)

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
por: Gobbi, Federico, et al.
Publicado: (2021)

SARS-CoV-2 BNT162b2 vaccine–induced humoral response and reactogenicity in individuals with prior COVID-19 disease
por: Kelsen, Steven G., et al.
Publicado: (2022)

Could Prior COVID-19 Affect the Neutralizing Antibody after the Third BNT162b2 Booster Dose: A Longitudinal Study
por: Erdem, Mustafa Genco, et al.
Publicado: (2023)

An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination: A Case Report
por: Ghincea, Alexander, et al.
Publicado: (2022)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_as9pik203rmtnm2c4hsicme5ft